Objectives

1. Review recent pathophysiological findings in AD that have informed the selection of new therapeutic targets

2.Describe best practices for severity assessment and diagnosis of moderate-to-severe AD in pediatric patients, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden

3. Explain the mechanisms of action and clinical profiles of new and emerging targeted systemic agents for the long-term treatment of AD in pediatric patients